2014_ICM.jpg

Presentation

  • 12 000 m2 dedicated to research
  • 500 researchers*recruited internationally
  • 100,000 neurological patients / year
  • 1 clinical investigation center (1200m2, 15 clinicians)
  • 7,000 m2 dedicated to technological platforms
  • Central Nervous System diseases from fondamental research to clinical investigation on:
    • Parkinson’s disease
    • Alzheimer’s and related diseases
    • Multiple sclerosis
    • Epilepsy
  • Five platforms of excellence dedicated to neurologys

http://icm-institute.org

Developing innovative solutions for patients is key to our mission, and ICM has assembled more than 500 researchers recruited internationally to have a strong neuroscience research rooted in the largest neurology practice of France. With nearly 100 000 neurological patients coming to Pitie-Salpetriere hospital each year for out-patient consultations, our Institute stands right in the center of where diseases are seen and managed. To understand in depth the disease, the same clinicians who have contact with patients in regular clinical practice are also involved in preclinical and clinical research within ICM - working at understanding normal and pathological brain states.
This is still not enough: To really make a difference, research collaborations with bright minds worldwide are essential to us. This holds true for our international academic network that is reflected in the variety of nationalities amongst our students and researchers, and is also true for our vivid interactions with private researchers of fields going from molecular diagnostics to digital health.

Current research interests

Five cutting-edge projects covering major neurological pathologies, with specific objectives for each of them

The aim will be to “fill the gaps” needed to establish a complete continuum in excellence in translational research in particular at precompetitive level, in care and in education on all of the five themes:

  • Parkinson’s disease: Prevent the evolution of the disease. The project aims at understanding the mechanisms of degeneration to find curative treatments with expected impact on neurodegenerative diseases at large.
  • Alzheimer’s and related diseases: Find new biomarkers for an earlier and better diagnosis. The project aims at an early diagnosis of neurological disorders.
  • Multiple sclerosis: Repair the nervous system for a clinical improvement of patients. The project aims at repairing the altered nervous system with expected impact on degenerative disorders but also trauma or cerebro-vascular diseases as whole.
  • Motivation: Understand and manage disorders of motivation, a novel approach for behavioral medical sciences. This project aims at correcting symptoms with a special emphasis on behavioral disorders and further extension to other nervous disorders.
  • Epilepsy: Anticipate and understand the development of the seizure. This project aims at identifying the symptoms as early as possible to prevent their development.

Five platforms of excellence to both support “in house” workpackages and open to new projects

  • Develop a cutting-edge neuro-imaging and neurophysiology platform to radically enhance diagnosis and follow-up of disease course.
  • Build a multidisciplinary data management, bioinformatics and biostatistics platform, critical to manage the enormous amount of data generated.
  • Implement new animal models for a better translational research at precompetitive level to test and confirm potential therapeutic targets identified in research activities.
  • Develop a cell culture core facility for medium throughput screening to accelerate the identification of therapeutical leads.
  • Extend the platform for clinical trials dedicated to neurosciences to significally reinforce the capability to conduct clinical trials, in particular with industrial partners.
The ICM addresses brain and spinal cord disorders by accelerating the development of new health solutions

Personalised Medicine

The ICM has structured its research strategy into key thematic and transversal axis according to the unmet needs of «translational» research in the field of Neuroscience.

Patient cohorts, biomarkers identification and the validation of new therapeutic targets allow for patients affected by Parkinson’s disease, Alzheimer’s disease, multiple sclerosis or neuro-oncological tumors to benefit from personalized diagnosis and foresight into how they will respond to treatments.

Medtech approaches

Identified biomarkers can be circulating molecules, neuroimaging signals, electroencephalographic traces, responses to cognitive tests or other «markers». Those new markers and their combination are identified at ICM by capitalizing on extensive patients cohorts and through the development of new technologies, used as measurement tools as well as a means to modulate brain activity: deep brain stimulation, therapeutic ultrasounds, transcranial magnetic stimulation, etc. are being developed at the ICM Carnot Institute thanks to 7,000 sqm of technological core facilities.

Digital tools for active ageing and disease monitoring

With the view of constructing a “hospital of the future”, promoting home-based care for patients and preventing age-related comorbidities, the ICM Carnot Institute is developing, thanks to its joint academia/industry laboratories and the innovative companies of its iPEPS-ICM incubator, ultra-early diagnostic tools for diseases and digital tools for maintaining patients’ autonomy: smartphone applications, connected devices, medical devices, serious games. In order to understand and manage motivation-related disorders, a unique living lab allows for experimentation around potential solutions.

Knowledge and know-how

  • Genetics
  • Transgenesis
  • Preclinical studies
  • Clinical trials
  • Neuroimaging
  • Biostatistics
  • Biomarker research

Examples of core facilities:

  • Virtual reality
  • MEG/EEG
  • MRI
  • Cellular imaging
  • Electrophysiology
  • Preclinical functional exploration

Partnerships

Partners in basic research

The collaborations extend well beyond France to meet global challenges and to be competitive in some highly dynamic areas of research.
The Brain & Spine Institute (ICM) researchers collaborate in large-scale European programs and maintain favored links with universities worldwide.

Industrial Partnerships

In parallel to its fundamental research activity, the Brain & Spine Institute (ICM) conducts applied research together with industrial partners. Common know-how and skills are shared in order to develop new products and services that can benefit to patients.
Several partnerships are ongoing with the industry, see examples in our Portfolio
These programs leverage both our clinical and our non-clinical expertise to set-up collaborative research with our partners, ranging from fundamental, to clinical, translational and applied research in various domains.

The Brain & Spine Institute (ICM) is sharing its expertises and its technological platforms (see Core Facilities) via the consortium GLOBAL CARE Initiative.

Many partnerships are ongoing with Roche, GenoSplice, Pfizer, Servier, GlaxoSmithKline, Sanofi, AirLiquide, UCB, MensiaTechnologies, IPSEN, Lilly...

See our Portfolio

GLOBAL CARE is an outstanding consortium of 5 French expertises :